Abstract
Clinical Question: What is the efficacy of pharmacologic interventions in preventing proliferative vitreoretinopathy? Bottom Line: There is limited high-quality evidence to support currently available pharmacological options for prevention of proliferative vitreoretinopathy.
| Original language | English |
|---|---|
| Pages (from-to) | 669-670 |
| Number of pages | 2 |
| Journal | JAMA Ophthalmology |
| Volume | 142 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 18 2024 |